A gastrointestinal lipase inhibitor reduces progression of atherosclerosis in mice fed a western-type diet

European Journal of Pharmacology

Volumn 501, Issue 1-3, 2004, Pages 137-142

  Ueshima, Koji ^a   Akihisa Umeno, Hitomi ^a   Nagayoshi, Akira ^a   Takakura, Shoji ^a   Matsuo, Masahiko ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Atherosclerosis; Fat absorption; Orlistat; Western type diet

Indexed keywords

APOLIPOPROTEIN E; ESTERASE INHIBITOR; OLIVE OIL; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET; ENZYME INHIBITION; HYPERLIPIDEMIA; KNOCKOUT MOUSE; LIPID ABSORPTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH JUICE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CHOLESTEROL, DIETARY; DIET, ATHEROGENIC; GASTROINTESTINAL TRACT; LACTONES; LIPASE; MALE; MICE; MICE, KNOCKOUT; TRIGLYCERIDES;

EID: 4644332927     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.08.014     Document Type: Article

References (24)

1. K. Ackroff, and A. Sclafani Effects of the lipase inhibitor orlistat on intake and preference for dietary fat in rats Am. J. Physiol. 271 1996 R48 R54
2. A. Ballinger, and S.R. Peikin Orlistat: its current status as an anti-obesity drug Eur. J. Pharmacol. 440 2002 109 117
3. T. Chiba, T. Nakazawa, K. Yui, E. Kaneko, and K. Shimokado VLDL induces adipocyte differentiation in apoE-dependent manner Arterioscler. Thromb. Vasc. Biol. 23 2003 1423 1429
4. P. Cullen Evidence that triglycerides are an independent coronary heart disease risk factor Am. J. Cardiol. 86 2000 943 949
5. H.R. Davis, D.S. Compton, L. Hoos, and G. Tezloff Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in apoE knockout mice Arterioscler. Thromb. Vasc. Biol. 21 2001 2032 2038
6. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
7. E. Fernandez, and B. Borgström Effects of tetrahydrolipstatin, a lipase inhibitor, on absorption of fat from the intestine of the rat Biochim. Biophys. Acta 1001 1988 249 255
8. A.M. Gotto Jr. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease Am. Heart J. 144 Supplement 6 2002 S33 S42
9. S. Hogan, A. Fleury, P. Hadvary, H. Lengsfeld, M.K. Meier, J. Triscari, and A.C. Sullivan Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase Int. J. Obes. 11 Suppl. 3 1987 35 42
10. W. McNeely, and P. Benfield Orlistat Drugs 56 1998 241 249
11. Y. Nakashima, A.S. Plump, E.W. Raines, J.L. Breslow, and R. Ross ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree Arterioscler. Thromb. 14 1994 133 140
12. J.R. Patsch, G. Miesenbock, T. Hopferwieser, V. Muhlberger, E. Knapp, J.K. Dunn, A.M. Gotto Jr., and W. Patsch Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state Arterioscler. Thromb. 12 1992 1336 1345
13. A.S. Plump, J.D. Smith, T. Hayek, Aalto-Setolo, A. Walsh, J.G. Verstuyft, E.M. Rubin, and J.L. Breslow Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells Cell 71 1992 343 353
14. J.B. Reitsma, M.C. Cabezas, T.W. de Bruin, and D.W. Erkelens Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor Metabolism 43 1994 293 298
15. H.S. Simpson, C.M. Williamson, T. Olivecrona, S. Pringle, J. Maclean, A.R. Lorimer, F. Bonnefous, Y. Bogaievsky, C.J. Packard, and J. Shepherd Postprandial lipemia, fenofibrate and coronary artery disease Atherosclerosis 85 1990 193 202
16. A. Tanaka, N. Tomie, T. Nakano, K. Nakajima, K. Yui, M. Tamura, and F. Numano Measurement of postprandial remnant-like particles (RLPs) following a fat-loading test Clin. Chim. Acta 275 1998 43 52
17. R.K. Tangirala, E.M. Rubin, and W. Palinski Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice J. Lipid Res. 36 1995 2320 2328
18. K. Tordjman, C. Bernal-Mizrachi, L. Zemany, S. Weng, C. Feng, F. Zhang, T.C. Leone, T. Coleman, D.P. Kelly, and C.F. Semenkovich PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice J. Clin. Invest. 107 2001 1025 1034
19. K. Tsutsumi, Y. Inoue, A. Shima, K. Iwasaki, M. Kawamura, and T. Murase The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis J. Clin. Invest. 92 1993 411 417
20. J.H. van de Kamer, H.H. ten Bokkel, and H.A. Weyers Rapid method for the determination of fat in feces J. Biol. Chem. 177 1949 347 355
21. M.S. Weintraub, I. Grosskopf, T. Rassin, H. Miller, G. Charach, H.H. Rotmensch, M. Liron, A. Rubinstein, and A. Iaina Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years BMJ 312 1996 936 939
22. H.W. Wilmink, M.B. Twickler, J.D. Banga, G.M. Dallinga-Thie, H. Eeltink, D.W. Erkelens, T.J. Rabelink, and E.S. Stroes Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles Cardiovasc. Res. 50 2001 577 582
23. K.C. Yu, and A.D. Cooper Postprandial lipoproteins and atherosclerosis Front. Biosci. 6 2001 D332 D354
24. S.H. Zhang, R.L. Reddick, B. Burkey, and N. Maeda Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption J. Clin. Invest. 94 1994 937 945